Pulse Oximetry_Performance During Severe Signal Interference - PCBA-1 (Printed Circuit Board Assembly)

December 5, 2013 updated by: Medtronic - MITG

Controlled Acute Hypoxia Studies Comparing Pulse Oximetry to Arterial Blood Samples During Motion in Healthy, Well-perfused Subjects With the Functional Monitoring PCBA-1

Determine accuracy specifications and labeling claims of a pulse oximeter in a diverse subject population during severe signal interference over a specified saturation range.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

17

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Colorado
      • Boulder, Colorado, United States, 80301
        • Covidien

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Healthy Well perfused

Description

Inclusion Criteria:

  1. Male or female subjects between the ages of 18 to 50 years (inclusive).
  2. Must undergo a physical examination by a licensed physician, advanced practice nurse or physician assistant, including a 12 lead ECG, a medical history, and a blood test checking complete blood count and screening for sickle cell trait or disease
  3. All female volunteers must have a negative urine pregnancy test prior to participation.

Exclusion Criteria:

  1. A room-air baseline % modulation < 1.5% on all four fingers on the test hand
  2. Pregnancy or lactating women
  3. History of syncopal episodes
  4. Hypertension (defined as a systolic pressure of >145 mmHg or a diastolic pressure >90 mm Hg on three consecutive readings)
  5. Premature ventricular contractions (PVC's) that are symptomatic or occur at a rate of more than 5/minute
  6. History of seizures (except childhood febrile seizures) or epilepsy
  7. Routine use of tranquilizers and/or excessive anxiety
  8. History of frequent headaches or migraines
  9. History of stroke
  10. Previous injury or trauma to fingers or hands that may change blood flow or vascular supply and affect our ability to test multiple sensors
  11. History of "altitude sickness" defined as headaches, malaise or dizziness when in the mountains or in an aircraft at altitude significantly above sea level for a prolonged period of time (> 1 hour)
  12. History of significant respiratory disease, such as severe asthma, emphysema, etc.
  13. Sickle cell disease or trait.
  14. The use of medications, pre-existing medical conditions, treatment for a medical condition or any other reason deemed relevant by the clinician conducting the study.
  15. A clinically significant abnormal finding on medical history, physical examination, clinical laboratory test or ECG. Clinical significance will be assessed by the principal investigator or designee.
  16. Prior or known allergies to lidocaine (or similar pharmacologic agents, e.g., Novocain)
  17. Prior or known allergies to heparin
  18. History of transient ischemic attacks or carotid artery disease
  19. History of myocardial ischemia, angina, myocardial infarction, congestive heart failure or cardiomyopathy
  20. History of chronic renal impairment
  21. History of recent arterial cannulation (less than 1 month prior to study)
  22. History of complications from previous arterial cannulation
  23. Current use of blood thinners

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
SpO2 Accuracy (percentage of blood oxygen saturation)
Time Frame: Duration of subject visit- approx. 1.5 hours
Duration of subject visit- approx. 1.5 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2012

Primary Completion (Actual)

November 1, 2012

Study Completion (Actual)

November 1, 2012

Study Registration Dates

First Submitted

November 27, 2012

First Submitted That Met QC Criteria

December 10, 2012

First Posted (Estimate)

December 11, 2012

Study Record Updates

Last Update Posted (Estimate)

December 6, 2013

Last Update Submitted That Met QC Criteria

December 5, 2013

Last Verified

December 1, 2013

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • COVMOPR0384

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

3
Subscribe